ResearcherShandong UniversityNo recent work listed
Shengbin Shi
Matched on OpenAlex author ID A5033825225. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper
Papers 3
- lncRNA MALAT1, HOTTIP and PVT1 as predictors for predicting the efficacy of GEM based chemotherapy in first-line treatment of pancreatic cancer patients. First author DOI 10.18632/oncotarget.19345↗
- [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer]. Co-author DOI 10.3760/cma.j.issn.0253-3766.2013.04.013↗
- Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2012.09.007↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zuoxing Niu · 2 shared papers, 2012–2017 · strength 0.13
- Paper lncRNA MALAT1, HOTTIP and PVT1 as predictors for predicting the efficacy of GEM based chemotherapy in first-line treatm… DOI 10.18632/oncotarget.19345↗
- Paper Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer. DOI 10.1016/j.pan.2012.09.007↗
- Jing Tian · 1 shared paper, 2017 · strength 0.09
- Cui-Juan Wang · 1 shared paper, 2017 · strength 0.09
- Chunhua Li · 1 shared paper, 2013 · strength 0.05
- Quan-yun Liu · 1 shared paper, 2012 · strength 0.04
- Meng Wang · 1 shared paper, 2012 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.